Takami Hiroya, Washio Kazunori, Gotoh Hiromichi
Saiyu Kawaguchi Clinic, Kawaguchi, Japan.
Saitama Honoka Clinic, Saitama, Japan.
Int J Nephrol. 2017;2017:6218129. doi: 10.1155/2017/6218129. Epub 2017 Aug 22.
Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients. We treated male hemodialysis patients with low radius BMD with denosumab therapy for 1 year and evaluated its effect on radius BMD. Seventeen patients were treated with denosumab 60 mg every 6 months, and 20 patients were not treated with denosumab (control group). At seven days, the mean corrected calcium level decreased from 9.2 ± 0.5 mg to 8.5 ± 0.5 mg ( < 0.01), and mean serum phosphorus decreased from 5.0 ± 1.3 mg/dl to 4.2 ± 0.9 mg/dl ( < 0.01). At 1 month, the corrected calcium and serum phosphorus levels were 9.2 ± 0.9 mg/dl and 4.0 ± 1.1 mg/dl, respectively. At 1 year, BMD increased by 2.6% ± 4.4% in the denosumab group and decreased by 4.5% ± 7.7% in the control group ( < 0.001). In our observational study, denosumab therapy represents an effective treatment for male dialysis patients with low BMD.
地诺单抗可增加未接受血液透析治疗患者的骨矿物质密度（BMD）。然而，关于地诺单抗在血液透析患者中的应用，文献中的数据有限。我们对低桡骨骨密度的男性血液透析患者进行了为期1年的地诺单抗治疗，并评估了其对桡骨骨密度的影响。17例患者每6个月接受60mg地诺单抗治疗，20例患者未接受地诺单抗治疗（对照组）。在第7天时，平均校正钙水平从9.2±0.5mg降至8.5±0.5mg（<0.01），平均血清磷从5.0±1.3mg/dl降至4.2±0.9mg/dl（<0.01）。在第1个月时，校正钙和血清磷水平分别为9.2±0.9mg/dl和4.0±1.1mg/dl。在第1年时，地诺单抗组的骨密度增加了2.6%±4.4%，而对照组降低了4.5%±7.7%（<0.001）。在我们的观察性研究中，地诺单抗治疗是低骨密度男性透析患者的一种有效治疗方法。
